Real-world meta-analysis of baricitinib for atopic dermatitis shows variable outcomes
Real-world data shows baricitinib helps European patients with severe eczema
This real-world meta-analysis of 264 European patients with moderate-severe atopic dermatitis found that baricitinib improved EASI scores at…
A new analysis of real-world patients found baricitinib reduced eczema severity and itch for many people with moderate-to-severe atopic derm…
Secondary analysis of Phase 3 trials shows lebrikizumab improves absolute EASI response in moderate-to-severe atopic dermatitis
New analysis shows lebrikizumab helps clear skin faster than placebo for atopic dermatitis
This secondary analysis of two Phase 3 trials evaluated lebrikizumab 250 mg Q2W versus placebo in adults and adolescents with moderate-to-se…
A look at two major trials found lebrikizumab led to significantly better skin clearing than placebo in adults and adolescents with moderate…
Narrative review explores gut microbiota links to atopic dermatitis pathogenesis and potential therapeutic strategies
Gut bacteria changes may offer new hope for atopic dermatitis
This narrative review examines the relationship between gut microbiota alterations and atopic dermatitis. The authors discuss dysbiosis, los…
A review suggests that gut microbiome imbalances and specific bacterial changes could play a role in skin inflammation, pointing to new prev…
Systematic review and meta-analysis of AI for melanoma risk assessment in pigmented skin lesions
AI plus doctors finds every skin cancer case in real-world settings
This systematic review and meta-analysis synthesized evidence from 17 diagnostic arms on AI, dermoscopy, and AI-assisted clinicians for mali…
When doctors used AI alongside standard skin checks, they caught every cancer case without missing any, showing a powerful new way to help p…
Review highlights emerging mechanisms for allergic contact dermatitis management
Critical gaps remain in understanding allergic contact dermatitis sensitization thresholds
This narrative review discusses allergic contact dermatitis and notes critical gaps persist regarding tissue-resident memory T cells and pre…
A review of allergic contact dermatitis highlights emerging mechanisms that may support the development of more precise and effective therap…
Marburg MS case shows treatment challenges and fatal outcome
A Rare MS Variant Defied Treatment Until This Switch
A 46-year-old woman with aggressive Marburg MS faced treatment-limiting toxicity and died despite multiple therapies, highlighting urgent ca…
A woman with a rare, aggressive form of multiple sclerosis tried many treatments without success, and doctors tried a new approach too late.
FDA Approves Wezlana (ustekinumab-ttwe) for Plaque Psoriasis, Psoriatic Arthritis, Crohn's Disease, and Ulcerative Colitis
FDA approves Wezlana, a biosimilar to Stelara, for several inflammatory conditions.
The FDA approved Wezlana (ustekinumab-ttwe), a biosimilar to Stelara, for moderate to severe plaque psoriasis, active psoriatic arthritis, m…
The FDA approved Wezlana (ustekinumab-ttwe), a biosimilar to Stelara, for plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcera…
FDA Approves Wezlana (ustekinumab-ttwe) for Plaque Psoriasis, Psoriatic Arthritis, Crohn's Disease, and Ulcerative Colitis
FDA approves Wezlana, a biosimilar to Stelara, for inflammatory conditions.
The FDA approved Wezlana (ustekinumab-ttwe), a biosimilar to Stelara, for multiple indications including plaque psoriasis, psoriatic arthrit…
The FDA approved Wezlana, a biosimilar to Stelara, for plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. It of…
FDA Approves Siliq (brodalumab) for Moderate to Severe Plaque Psoriasis
FDA approves new drug Siliq for adults with plaque psoriasis
The FDA approved Siliq (brodalumab) for adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or photother…
The FDA approved Siliq (brodalumab) for adults with moderate to severe plaque psoriasis who have not responded well to other treatments. Thi…
Narrative review of treatment strategies for primary central nervous system lymphoma
A Smarter Way to Treat a Rare Brain Lymphoma Is Emerging
This narrative review covers treatment strategies for primary central nervous system lymphoma, including HD-MTX-based regimens, HDC-ASCT, an…
A rare lymphoma hiding in the brain now has sharper risk tools and smarter drug combos that could mean fewer relapses and less toxic treatme…
Review of case report suggests multimodal therapy potential for unresectable intraductal papillary mucinous neoplasms of the bile duct
At-a-Glance
This review of a case report describes two patients with unresectable intraductal papillary mucinous neoplasms of the bile duct treated with…
A new three-drug combination shrank a rare bile duct tumor in one patient and stopped another from growing, offering hope for a cancer with …
Narrative review offers theoretical basis for selecting biologic therapies in psoriasis patients with renal concerns
New Psoriasis Treatments May Protect Kidneys While Fighting Skin Flares
This narrative review examines the use of TNF-alpha, IL-17, and IL-12/23 inhibitors in psoriasis patients with renal concerns. The authors p…
• Some biologics shield kidneys from damage during psoriasis treatment • Helps the 8 million Americans with psoriasis and kidney worries • N…